Bangladesh Pharmaceutiicals and Healthcare Report Q3 2011

Date: June 22, 2011
Pages: 88
US$ 1,295.00
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Download

Download PDF Leaflet

Includes 3 FREE quarterly updates

BMI View: Bangladesh’s pharmaceutical industry, which was worth US$1.40bn in 2010, is fairly typical for South Asia. Growth is high but per-capita spending remains low. The market is also characterised by the ability of those on high incomes to purchase expensive patented drugs, while the vast majority of the population make do with frequently sub-standard over-the-counter (OTC) preparations. Local pharmaceutical companies and those multinationals with manufacturing facilities in Bangladesh cater for approximately 95% of domestic demand. Of the 49 UN-decreed Least Developed Countries (LDCs), Bangladesh is the only one that is nearly self-sufficient in terms of pharmaceutical production.

Headline Expenditure Projections
  • Pharmaceuticals: BDT97.45bn (US$1.40bn) in 2010 to BDT113.14bn (US$1.59bn) in 2011; +16.1% in local currency terms and +13.5% in US dollar terms. Forecast up moderately from Q211 due to macroeconomic factors.
  • Healthcare: BDT242bn (US$3.48bn) in 2010 to BDT269bn (US$3.78bn) in 2011; +11.3% in local currency terms and +8.8% in US dollar terms. Forecast unchanged from Q211.
  • Medical devices: BDT11.47bn (US$165mn) in 2010 to 12.55bn (US$176mn) in 2011; +9.4% in local currency terms and +7.0% in US dollar terms. Forecast up marginally from Q211 due to analyst modification.
Business Environment Rating: Bangladesh’s pharmaceutical Business Environment Rating (BER) in Q311 remains unchanged at 40.6 out of 100, which is well below the average of 53.1 for the region. The country has moved down one place to occupy 15th position, behind Pakistan and has an unchanged Industry Rewards score of 43. Despite its current ranking, BMI expects Bangladesh’s position to improve over the medium term as a result of rising population numbers, economic improvements and the efforts made by domestic firms to expand both their products portfolios and overseas markets.

Key Trends & Developments
  • The Bangladesh government announced that it would establish an active pharmaceuticals ingredient (API) industrial park to aid the local pharmaceutical industry and boost exports. It is hoped that the majority of pharmaceutical raw materials could be produced locally when the project is implemented in 2012. The planned investment is also designed to provide a stimulus to contract manufacturing capabilities in Bangladesh. Estimates suggest that the domestic pharmaceutical sector could earn approximately BDT200bn (US$2.72bn) per year.
  • Figures derived from the latest Household Income and Expenditure Survey has revealed that the level of poverty in Bangladesh has dropped to 31.5% over the course of 2010, reflecting an 8.5 percentage point decline over the last five years. The findings of the latest HIES report compiled by the Bangladesh Bureau of Statistics has shown that the reduction of poverty levels in rural areas has played a key role in reducing the prevalence of hunger in the country.
  • The number of diabetic patients in Bangladesh is increasing at an alarming rate with approximately 5.7mn people diagnosed with the disease. The number of patients is growing annually at a rate of 3%, with estimates suggesting that at current growth rates, the number of diabetics in Bangladesh could reach 10.4mn by 2030. At present, India and Bangladesh have the highest number of diabetic patients in the South-East Asian region.
  • A report published in April 2011 suggests that elderly people living in Dhaka’s slums are highly vulnerable to illness due to an absence of basic civic amenities. The report has found that poor, elderly people in the capital’s slums face numerous challenges in obtaining healthcare, financial support, work opportunities, an improved living environment and infrastructure development.
BMI Economic View: As Bangladesh’s economy develops, drug market expenditure as a percentage of GDP is forecast to increase from 1.4% in 2010, to 1.5% in 2020. Increased wealth should translate into greater out-of-pocket spending by consumers and a greater proportion of public funds being directed to healthcare projects, especially among the poor. The main drivers of medicine sales in Bangladesh will therefore stem from increased government involvement in healthcare, a greater prevalence of chronic disease in high-income groups and the adoption of modern marketing techniques by local drug manufacturers.

BMI Political View: The Bangladesh government is committed to expanding access to medical services in general and pharmaceuticals in particular. Under the constitution of the People’s Republic of Bangladesh (amended May 17 2004), the state regards ‘raising the level of nutrition and the improvement of public health’ as one of its primary duties. Although healthcare is mainly provided through government-run hospitals or private clinics, the country’s state-run healthcare facilities are oversubscribed, short-staffed and lacking equipment, especially those outside of the large cities. Nevertheless, efforts are being made to improve healthcare services.
Executive Summary
SWOT Analysis
Bangladesh Pharmaceuticals And Healthcare Industry SWOT
Bangladesh Political SWOT
Bangladesh Economic SWOT
Bangladesh Business Environment SWOT
Pharmaceutical Business Environment Ratings
    Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q311
Market Summary
Regulatory Regime
    Table: Steps Required To Establish Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence (DML)
Counterfeit Drugs
Intellectual Property
Pricing And Reimbursement Regime
Industry Trends And Developments
Healthcare Sector
Contract Manufacturing
Research And Development
    Table: Suggestions Made By University Of Dhaka’s Faculty Of Pharmacy To Improve Pharmaceutical Research Standards
Industry Forecast Scenario
Overall Market Forecast
    Table: Pharmaceutical Sales Indicators 2007-2015
Key Growth Factors – Industry
    Table: Health Expenditure Indicators 2007-2015
    Table: Government Health Expenditure Indicators 2007-2015
    Table: Private Health Expenditure Indicators 2007-2015
Macroeconomic Forecast
    Table: Bangladesh – Economic Activity
Prescription Drug Market Forecast
    Table: Prescription Drug Sales Indicators 2007-2015
Patented Drug Market Forecast
    Table: Patented Drug Sales Indicators 2007-2015
Generic Drug Market Forecast
    Table: Generic Drug Sales Indicators 2007-2015
OTC Medicine Market Forecast
    Table: OTC Medicine Sales Indicators 2007-2015
Pharmaceutical Trade Forecast
    Table: Pharmaceutical Imports & Exports Indicators 2007-2015
Other Healthcare Data Forecasts
Key Risks To BMI’s Forecasts
Competitive Landscape
Recent Activities By Foreign Companies
Recent Activities By Domestic Companies
Company Profiles
Indigenous Companies
Eskayef Bangladesh
Square Pharmaceuticals
Beximco Pharmaceuticals
Country Snapshot: Bangladesh Demographic Data
Section 1: Population
    Table: Demographic Indicators, 2005-2030
    Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
    Table: Education, 2001-2003
    Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
    Table: Employment Indicators, 2001-2006
    Table: Consumer Expenditure, 2000-2010 (US$)
    Table: Average Annual Manufacturing Wages
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings Overview
    Table: Pharmaceutical Business Environment Indicators
    Table: Weighting Of Components
Skip to top

Bangladesh Pharmaceuticals and Healthcare Report Q4 2015 US$ 1,295.00 Sep, 2015 · 100 pages
The Medical Device Market: Bangladesh US$ 1,295.00 Jan, 2014 · 132 pages

Ask Your Question

Bangladesh Pharmaceutiicals and Healthcare Report Q3 2011
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: